Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, $50 Price Target

Ascendiant Capital maintained a Buy rating on NRX Pharmaceuticals with a price target of $50.00, implying an upside of 1612.3% from the Sep 30 close.